With an eye on the lucrative U.S. market, Italy’s Angelini Pharma will acquire rare disease specialist Catalyst Pharmaceuticals and its potential blockbuster, Firdapse, for $4.1 billion. Rome-based ...

Rare-disease specialist Catalyst Pharmaceuticals is set to be acquired by healthcare group Angelini Pharma in a $4.1 billion deal. Angelini will pay $31.50 for each of Nasdaq-listed Catalyst’s ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. The Italian company Angelini Pharma ...

State-backed CDP Equity to have a stake in combined entity Deal comes after Chiesi's $1.9 billion buyout of U.S. KalVista Angelini aims to create global player in rare disease drugs ROME/MILAN, May 7 ...

Meta Platforms, Inc. delivered robust Q1 2026 results, with revenue up 33% to $56.31B and EPS beating estimates by 7.2%. Despite strong fundamentals, META shares fell 6% post-earnings due to a raised ...

Several Weld County employees have been afraid to go to the press or County Council for the fear of getting in trouble, if they expose an issue with the proposed judicial center that the county ...

Italian drugmaker Angelini Pharma is exploring a potential acquisition of Catalyst Pharmaceuticals Inc. as it looks at deals to expand its footprint globally, people familiar with the matter said.

Travel technology add-on Tripkicks has launched a new platform to guide traveler decisions throughout their trip, drawing from corporate travel data and behavioral science, the company said. The ...

Applying the 1.198 adjustment factor to the $90.30 base produces our final 24/7 Wall St. Price Target of $108.18. The technology sector momentum tailwind lifts the target materially, while the high ...